Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 afatinib study in advanced non-small cell lung cancer with uncommon EGFR mutations
jRCTs041190027Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Objective response rate. Started Jan 2020; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041190027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190027.